Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02410902 · ClinicalTrials.gov registry record · Phase 3
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)
A Phase 3 study, sponsored by Curemark.
- Completed
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
NCT02410902 is a Phase 3 study that has completed, run by Curemark. The registered enrollment target is 190 participants.
The verdict
NCT02410902, a Phase 3 study, has completed, sponsored by Curemark.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism in children with all levels of fecal chymotrypsin.
Interventions
- DRUG PLACEBO
- DRUG CM-AT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2015-05-13 |
| Est. Completion | 2017-12-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02410902
The ClinicalTrials.gov registry entry for NCT02410902 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Curemark, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PLACEBO is the first listed.
NCT02410902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02410902 about?
NCT02410902 is a clinical study titled "A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)". The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism in children with all levels of fecal chymotrypsin.
What is the current status of trial NCT02410902?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2015-05-13. Estimated completion is 2017-12-22.
What interventions are being tested in trial NCT02410902?
The interventions under investigation include: PLACEBO (DRUG), CM-AT (DRUG).
Who is sponsoring clinical trial NCT02410902?
This trial is sponsored by Curemark, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.